ArticleBlood cancer journal2025
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases.
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07636486 (Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Who cites it
2 citing papers in PubMed.
- Luspatercept for the treatment of transfusion-dependent non-severe aplastic anemia.Annals of hematology · 2026Article
- TGF-β1-triggered maladaptive bone marrow endothelium impedes hematopoietic recovery.Signal transduction and targeted therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.